A_randomized_double-blind_study_of_gallium_nitrate_compared_with_etidronate_for_acute_control_of_cancer-related_hypercalcemia._Hypercalcemia_is_a_major_source_of_morbidity_and_mortality_in_patients_with_cancer._Gallium_nitrate_and_the_bisphosphonate,_etidronate,_are_new_agents_that_have_recently_become_available_for_treatment_of_this_disorder._To_directly_compare_therapeutic_effectiveness,_we_conducted_a_randomized,_double-blind,_multicenter_study_of_gallium_nitrate_compared_with_etidronate_for_acute_control_of_cancer-related_hypercalcemia._Gallium_nitrate_was_administered_by_continuous_intravenous_(IV)_infusion_at_a_dose_of_200_mg/m2/d._Etidronate_was_administered_as_a_4-hour_IV_infusion_at_a_dose_of_7.5_mg/kg._Both_drugs_were_given_daily_for_5_consecutive_days._Eligible_patients_had_persistent_moderate-to-severe_hypercalcemia_(total_serum_calcium_corrected_for_serum_albumin_greater_than_or_equal_to_12.0_mg/dL)_after_2_days_of_hospitalization_and_IV_hydration._Seventy-one_patients_were_randomized_and_treated._Twenty-eight_of_34_patients_(82%)_who_received_gallium_nitrate_achieved_normocalcemia_compared_with_16_of_37_patients_(43%)_who_received_etidronate_(P_less_than_.001)._Patients_who_received_etidronate_required_significantly_greater_amounts_of_IV_fluids_(P_=_.04)_and_more_hypocalcemic_drug_treatment_(P_less_than_.05)_during_the_poststudy_period_than_patients_who_received_gallium_nitrate._Kaplan-Meier_analysis_showed_a_significantly_longer_median_duration_of_normocalcemia_for_patients_treated_with_gallium_nitrate_(8_days_v_0_days,_P_=_.0005)._A_significantly_higher_proportion_of_patients_treated_with_gallium_nitrate_developed_asymptomatic_hypophosphatemia_compared_with_patients_treated_with_etidronate_(97%_v_43%,_P_less_than_.001)._We_conclude_that_gallium_nitrate_is_highly_effective_and_superior_to_etidronate_for_acute_control_of_moderate-to-severe_cancer-related_hypercalcemia.